Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer
Carles Lavila, Misericordia
Sala i Serra, Maria
Pla Farnós, Roger
Interval Cancer Study Group
MetadataShow full item record
The one-size-fits-all paradigm in organized screening of breast cancer is shifting towards a personalized approach. The present study has two objectives: 1) To perform an economic evaluation and to assess the harm-benefit ratios of screening strategies that vary in their intensity and interval ages based on breast cancer risk; and 2) To estimate the gain in terms of cost and harm reductions using risk-based screening with respect to the usual practice. We used a probabilistic model and input data from Spanish population registries and screening programs, as well as from clinical studies, to estimate the benefit, harm, and costs over time of 2,624 screening strategies, uniform or risk-based. We defined four risk groups, low, moderate-low, moderate-high and high, based on breast density, family history of breast cancer and personal history of breast biopsy. The risk-based strategies were obtained combining the exam periodicity (annual, biennial, triennial and quinquennial), the starting ages (40, 45 and 50 years) and the ending ages (69 and 74 years) in the four risk groups. Incremental cost-effectiveness and harm-benefit ratios were used to select the optimal strategies. Compared to risk-based strategies, the uniform ones result in a much lower benefit for a specific cost. Reductions close to 10% in costs and higher than 20% in false-positive results and overdiagnosed cases were obtained for risk-based strategies. Optimal screening is characterized by quinquennial or triennial periodicities for the low or moderate risk-groups and annual periodicity for the high-risk group. Risk-based strategies can reduce harm and costs. It is necessary to develop accurate measures of individual risk and to work on how to implement risk-based screening strategies.
Is part ofPLoS One, 2014, vol. 9, núm. 2, p. e86858
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by, (c) Vilaprinyo et al., 2014
Showing items related by title, author, creator and subject.
Carles Lavila, Misericordia; Vilaprinyo Terré, Ester; Cots, Francesc; Gregori Gomis, Aleix; Pla Farnós, Roger; Román, Rubén; Sala i Serra, Maria; Macià, Francesc; Castells, Xavier; Rué i Monné, Montserrat (BioMed Central, 2011)Background: Breast cancer (BC) causes more deaths than any other cancer among women in Catalonia. Early detection has contributed to the observed decline in BC mortality. However, there is debate on the optimal screening ...
Impact of risk factors on different interval cancer subtypes in a population-based breast cancer screening programme Blanch, Jordi; Sala i Serra, Maria; Ibáñez, Josefa; Domingo, Laia; Fernández, Belén; Otegi, Arantza; Barata, Teresa; Zubizarreta, Raquel; Ferrer, Joana; Castells, Xavier; Rué i Monné, Montserrat; Salas, Dolores; Interval Cancer Study Group (Public Library of Science, 2014-10-21)Background: Interval cancers are primary breast cancers diagnosed in women after a negative screening test and before the next screening invitation. Our aim was to evaluate risk factors for interval cancer and their subtypes ...
Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain Domingo, Laia; Salas, Dolores; Zubizarreta, Raquel; Baré, Marisa; Sarriugarte, Garbiñe; Barata, Teresa; Ibáñez, Josefa; Blanch, Jordi; Puig-Vives, Montserrat; Fernández, Ana Belén; Castells, Xavier; Sala i Serra, Maria; Interval Cancer Study Group (BioMed Central, 2014)Introduction: Interval cancers are tumors arising after a negative screening episode and before the next screening invitation. They can be classified into true interval cancers, false-negatives, minimal-sign cancers, and ...